Ranolazine: New Paradigm for Management of Myocardial Ischemia, Myocardial Dysfunction, and Arrhythmias

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 603-614

  Stone, Peter H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angina; Diastolic dysfunction; Heart failure; Myocardial ischemia; Ranolazine

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIHYDROPYRIDINE; DILTIAZEM; KETOCONAZOLE; MACROLIDE; NITRATE; PLACEBO; RANOLAZINE; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; ASTHENIA; CALCIUM ABSORPTION; CONSTIPATION; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; DIZZINESS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; EXERCISE TOLERANCE; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HEART VENTRICLE ARRHYTHMIA; HUMAN; ISCHEMIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MORTALITY; MYOCARDIAL DISEASE; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SODIUM ABSORPTION; SODIUM CURRENT; ST SEGMENT ELEVATION; SUSTAINED RELEASE FORMULATION; SYNCOPE; SYSTOLIC DYSFUNCTION;

ACETANILIDES; ANGINA PECTORIS; ANIMALS; ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHIES; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; PIPERAZINES;

EID: 53149087116     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.06.002     Document Type: Review

References (26)

1. Gibbons R.J., Abrams J., Chatterjee K., et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41 (2003) 159-168
2. McCormack J.G., Barr R.L., Wolff A.A., et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93 (1996) 135-142
3. MacInnes A., Fairman D.A., Binding P., et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93 (2003) e26-e32
4. Belardinelli L., Antzelevitch C., and Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 6 (2004) 13-17
5. Undrovinas A.I., Belardinelli L., Undrovinas N.A., et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17 Suppl 1 (2006) S169-S177
6. Antzelevitch C., Belardinelli L., Zygmunt A.C., et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110 (2004) 904-910
7. Belardinelli L., Shryock J.C., and Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 8 (2006) A10-A13
8. Song Y., Shryock J.C., Wu L., et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44 (2004) 192-199
9. Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113 (2006) 2462-2472
10. Stone P.H., Chaitman B.R., Koren A., et al. Effects of ranolazine as monotherapy and combination therapy on rate pressure product at rest and during exercise: results from the MARISA and CARISA trials. Circulation 114 Suppl II (2006) II-715
11. Rousseau M.F., Pouleur H., Cocco G., et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 95 (2005) 311-316
12. Chaitman B.R., Skettino S.L., Parker J.O., et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43 (2004) 1375-1382
13. Chaitman B.R., Pepine C.J., Parker J.O., et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291 (2004) 309-316
14. Stone P.H., Gratsiansky N.A., Blokhin A., et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 48 (2006) 566-575
15. Morrow D.A., Scirica B.M., Karwatowska-Prokopczuk E., et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 297 (2007) 1775-1783
16. Scirica B.M., Morrow D.A., Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116 (2007) 1647-1652
17. Morrow D.A., Scirica B.M., Sabatine M.S., et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST elevation acute coronary syndromes in the MERLIN-TIMI 36 Trial. Circulation 116 Suppl II (2007) II-382
18. Sossalla S., Wagner S., Rasenack E.C., et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts-role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45 (2008) 32-43
19. Matsumura H., Hara A., Hashizume H., et al. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate. Jpn J Pharmacol 77 (1998) 31-39
20. Sabbah H.N., Chandler M.P., Mishima T., et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8 (2002) 416-422
21. Chandler M.P., Stanley W.C., Morita H., et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 91 (2002) 278-280
22. Aaker A., McCormack J.G., Hirai T., et al. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 28 (1996) 353-362
23. Hayashida W., van Eyll C., Rousseau M.F., et al. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 8 (1994) 741-747
24. Rousseau M.F., Cocco G., Bouvy T., et al. Effects of a novel metabolic modulator, ranolazine, on exercise tolernace and left ventricular filling dynamics in patients with angina pectoris. Circulation 86 Suppl I (1992) I-714
25. Rousseau M.F., Van Eyll C., Van Mechelen H.V., et al. Novel metabolic modulator ranolazine selectively improves diastolic function in heart failure. Circulation 86 Suppl I (1992) I-375
26. Moss A., Zareba W.Z., Schwarz K.Q., et al. Ranolazine shortens repolarization and improves myocardial relaxation in patients with type-3 long QT syndrome. J Am Coll Cardiol 51 Suppl A (2008) A15